Holen Sie sich die Stockscreener-App
45.33
4.06%
-1.92
Handel nachbörslich:
45.33
Schlusskurs vom Vortag:
$47.25
Offen:
$47.6
24-Stunden-Volumen:
587.84K
Relative Volume:
1.50
Marktkapitalisierung:
$2.58B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-118.49M
KGV:
-
EPS:
-
Netto-Cashflow:
$-110.57M
1W Leistung:
-25.02%
1M Leistung:
-15.32%
6M Leistung:
-9.90%
1J Leistung:
+147.70%
1-Tages-Spanne:
$45.11
$48.37
1-Wochen-Bereich:
$45.11
$61.05
52-Wochen-Spanne:
$16.39
$72.29
Apogee Therapeutics Inc Stock (APGE) Company Profile
Firmenname
Apogee Therapeutics Inc
Sektor
Branche
Telefon
650-394-5230
Adresse
221 CRESCENT ST., WALTHAM
Vergleichen Sie APGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| APGE | 45.33 | 2.58B | 0 | -118.49M | -110.57M | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-10 | Eingeleitet | BofA Securities | Buy |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | Guggenheim | Buy |
| 2023-08-08 | Eingeleitet | Jefferies | Buy |
| 2023-08-08 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - The Manila Times
Apogee Therapeutics Unveils First R&D Day: Spotlight on APG777 and Immunology Pipeline | APGE Stock News - StockTitan
Wedbush Forecasts Lower Earnings for Apogee Therapeutics - MarketBeat
Driehaus Capital Management LLC Acquires Shares in Apogee Therap - GuruFocus.com
Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Stifel maintains Buy on Apogee Therapeutics with $95 target - Investing.com India
FMR LLC Adjusts Stake in Apogee Therapeutics Inc - GuruFocus.com
Apogee Therapeutics Highlights Pipeline Progress and Financials - TipRanks
APGEApogee Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Stifel maintains Buy on Apogee Therapeutics with $95 target By Investing.com - Investing.com UK
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Apogee Reports Promising APG777 Trial Data, $754M Cash Runway Through 2028 | APGE Stock News - StockTitan
Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis - Seeking Alpha
Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 6,665 Shares - MarketBeat
Michael Thomas Henderson Sells 15,000 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics Inc (APGE) Worth Considering For The Next Few Weeks - Stocks Register
Insider Sale at Apogee Therapeutics Inc (APGE): Chief Medical Of - GuruFocus.com
Apogee Therapeutics chief medical officer sells shares worth $394,041 - Investing.com India
Apogee Therapeutics CEO sells shares worth $888,320 - Investing.com
Apogee Therapeutics chief medical officer sells shares worth $394,041 By Investing.com - Investing.com UK
(APGE) Proactive Strategies - Stock Traders Daily
Apogee Therapeutics (NASDAQ:APGE) and Fennec Pharmaceuticals (NASDAQ:FENC) Financial Contrast - Defense World
Apogee Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewswire
Jade, another biotech spinout of Paragon, to merge with Aerovate - BioPharma Dive
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
(APGE) Investment Analysis and Advice - Stock Traders Daily
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Wedbush Reiterates Outperform Rating for Apogee Therapeutics (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics Unveils Promising Phase 1 Trial Results - TipRanks
Apogee Therapeutics Announces Results Up to 9 Months from - GlobeNewswire
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel - The Bakersfield Californian
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases - StockTitan
Waypoint Capital Advisors LLC Invests $36.84 Million in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Trading Down 4.1%Here's What Happened - MarketBeat
(APGE) Technical Pivots with Risk Controls - Stock Traders Daily
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting - GlobeNewswire
11,535 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by AQR Capital Management LLC - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Down 11.7% in September - MarketBeat
Millennium Management LLC Lowers Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by The Manufacturers Life Insurance Company - MarketBeat
Analyzing Apogee Therapeutics Inc. (APGE) After Recent Trading Activity - Knox Daily
Ratio Examination: Apogee Therapeutics Inc. (APGE)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now - Insider Monkey
Squarepoint Ops LLC Purchases 25,829 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics executive sells over $370k in company stock - Investing.com India
Apogee Therapeutics Inc CEO Michael Henderson Sells 40,000 Shares - GuruFocus.com
Carl Dambkowski Sells 6,665 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics CEO sells over $2.2 million in company stock By Investing.com - Investing.com Canada
Apogee Therapeutics executive sells over $370k in company stock By Investing.com - Investing.com Australia
Apogee Therapeutics CEO sells over $2.2 million in company stock - Investing.com
Finanzdaten der Apogee Therapeutics Inc-Aktie (APGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):